Survival Strategies of Streptococcus pyogenes in Response to Phage Infection by Beerens, Dior et al.
viruses
Article
Survival Strategies of Streptococcus pyogenes in Response to
Phage Infection




Citation: Beerens, D.; Franch-Arroyo,
S.; Sullivan, T.J.; Goosmann, C.;
Brinkmann, V.; Charpentier, E.
Survival Strategies of Streptococcus
pyogenes in Response to Phage





Received: 3 March 2021
Accepted: 28 March 2021
Published: 2 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Max Planck Unit for the Science of Pathogens, 10117 Berlin, Germany; beerens@mpusp.mpg.de (D.B.);
arroyo@mpusp.mpg.de (S.F.-A.); Timothy.J.Sullivan@darthmouth.edu (T.J.S.)
2 Institute for Biology, Faculty of Life Sciences, Humboldt University Berlin, 10115 Berlin, Germany
3 Core Facility Microscopy, Max Planck Institute for Infection Biology, 10117 Berlin, Germany;
goosmann@mpiib-berlin.mpg.de (C.G.); brinkmann@mpiib-berlin.mpg.de (V.B.)
* Correspondence: research-charpentier@mpusp.mpg.de
† Current address: Department of Biomedical Data Science, Dartmouth College, Hanover, NH 03775, USA.
Abstract: Bacteriophages exert strong evolutionary pressure on their microbial hosts. In their lytic
lifecycle, complete bacterial subpopulations are utilized as hosts for bacteriophage replication. How-
ever, during their lysogenic lifecycle, bacteriophages can integrate into the host chromosome and
alter the host’s genomic make-up, possibly resulting in evolutionary important adjustments. Not
surprisingly, bacteria have evolved sophisticated immune systems to protect against phage infection.
Streptococcus pyogenes isolates are frequently lysogenic and their prophages have been shown to be
major contributors to the virulence of this pathogen. Most S. pyogenes phage research has focused
on genomic prophages in relation to virulence, but little is known about the defensive arsenal of S.
pyogenes against lytic phage infection. Here, we characterized Phage A1, an S. pyogenes bacteriophage,
and investigated several mechanisms that S. pyogenes utilizes to protect itself against phage predation.
We show that Phage A1 belongs to the Siphoviridae family and contains a circular double-stranded
DNA genome that follows a modular organization described for other streptococcal phages. After
infection, the Phage A1 genome can be detected in isolated S. pyogenes survivor strains, which enables
the survival of the bacterial host and Phage A1 resistance. Furthermore, we demonstrate that the
type II-A CRISPR-Cas system of S. pyogenes acquires new spacers upon phage infection, which
are increasingly detectable in the absence of a capsule. Lastly, we show that S. pyogenes produces
membrane vesicles that bind to phages, thereby limiting the pool of phages available for infection.
Altogether, this work provides novel insight into survival strategies employed by S. pyogenes to
combat phage predation.
Keywords: Streptococcus pyogenes; bacteriophage defense; Phage A1; CRISPR-Cas; membrane vesi-
cles; capsule
1. Introduction
The so-called “flesh-eating bacterium” Streptococcus pyogenes is a Gram-positive β-
hemolytic pathogen that strictly infects humans in natural settings [1,2]. Although S. pyo-
genes can colonize the throat and skin asymptomatically [3], the hallmark of S. pyogenes
is its ability to cause a vast variety of diseases [4]. Clinical manifestations of S. pyogenes-
infections range from superficial skin infections and pharyngitis to toxin-mediated diseases
(e.g., streptococcal toxic shock syndrome (STSS)), and invasive disease in subcutaneous
tissues [5].
With an estimated 616 million pharyngitis cases, almost 2 million severe S. pyogenes
disease cases and more than 500,000 deaths per year, S. pyogenes remains among the top
10 individual pathogens causing morbidity and mortality [6]. To date, S. pyogenes has
remained universally susceptible to penicillin, which remains the drug of choice to treat
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pharyngeal infections as well as for complicated or invasive infections [7]. Although no
penicillin-resistant S. pyogenes strains have been observed in clinical settings, up to 40%
treatment failure of severe S. pyogenes-associated disease with these antibiotics has been
reported [8]. These high mortality and treatment failure rates—despite the use of adequate
antimicrobials—call for effective alternatives. One alternative to antibiotics that has recently
gained an increasing momentum is phage therapy [9]. However, bacteriophages are known
to play important roles in the shaping of bacterial populations as well as the dissemination
of bacterial genetic material to new strains, potentially resulting in the spread of virulence
factors and antibiotic resistance genes [10].
The M protein is considered a major virulence determinant for S. pyogenes [11], since
emm gene knock-out (KO) mutants are neither able to survive in mouse models nor in hu-
man phagocyte-containing blood [12,13]. Additionally, M protein hyperproduction inhibits
phage adsorption, which results in phage-resistant S. pyogenes mutants [14], suggesting
that the M protein could serve a dual function in both phage and phagocyte resistance.
Another important virulence factor of S. pyogenes is the hyaluronic acid (HA) capsule,
which is chemically identical to HA produced by mammalian tissues [15]. This molecular
mimicry between the bacterial surface and host molecules reduces the ability of the host
immune system to detect and kill S. pyogenes. Indeed, encapsulated S. pyogenes strains are
associated with more severe disease [16] and were shown to be more resistant to neutrophil-
mediated killing in mice [17]. Early studies have also shown that enzymatic removal of
the HA capsule increased phage infectivity, suggesting that it provides a barrier between
bacteriophages and their bacterial surface-based receptor [18]. The biosynthesis of the HA
capsule is regulated by the hasABC operon [19], but only HasA and HasB are required for
the production of the HA capsule [20]. The hasABC operon is regulated by the Control of
Virulence (CovRS) two-component system [21], and spontaneous mutations within covRS
result in highly encapsulated and invasive S. pyogenes strains [22].
S. pyogenes isolates are frequently lysogenic, and most S. pyogenes phage research
has focused on genomic prophages in relation to horizontal gene transfer (HGT) and
virulence, but surprisingly little is known about the interplay between S. pyogenes and its
lytic phages [23]. The few reported lytic phages include Phage A1, A6, A12, A25 and A27;
however, only Phage A25 has been studied in detail to date [18,24,25]. Phage A25 belongs
to the Siphoviridae family [26], with low burst sizes ranging from 12 to 32 plaque-forming
units (PFUs) per infected cell depending on the host strain [27,28]. Host recognition is
thought to be a two-step process, as peptidoglycan was shown to be the cell receptor
for Phage A25 that mediated reversible adsorption, but an unknown additional factor
is required for irreversible binding and DNA injection [29]. Lytic S. pyogenes Phages A6,
A12, A25 and A27 have a broad host range and are able to infect some strains of Group C
Streptococci (GCS), and Phage A25 was shown to be adaptable to Group G Streptococci
(GGS) [25,29]. Recently, the genome sequence of Phage A25 has been determined to be
33,900 bp in size with a GC content of 38.44% [30]. The phages of S. pyogenes comprise a
modular genetic arrangement with regions dedicated to gene regulation, DNA replication,
DNA cleavage, DNA packaging, capsid and tail morphogenesis and lysis. In contrast to
most prophages of S. pyogenes, however, no identifiable virulence genes were found in the
genome of Phage A25 [30]. Genomic analysis of the Phage A25 and prophage genomes
provided hints towards the broad host range of S. pyogenes phages. A highly mosaic nature
of these genomes was identified, and genetic modules were shown to be shared between
phages of S. pyogenes, Streptococcus pneumoniae and Streptococcus suis, among others [30].
In this study, we demonstrate that Phage A1 is not a strictly lytic phage as previously
reported and we shed light on immune strategies of S. pyogenes to withstand phage in-
fection. We observe that membrane vesicles (MVs) produced by S. pyogenes are able to
scavenge phages from the environment and reduce the infection pressure. Additionally, S.
pyogenes produces a hyaluronic acid capsule that prevents phages to bind to their receptor.
Interestingly, CRISPR-Cas-mediated spacer acquisition is increased in the absence of the
capsule. In a minor fraction of infected cells, the Phage A1 genome is detectable in the S.
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pyogenes genome, which enables the survival of the bacterial host. Phage A1-surviving
clones neither become more virulent than their WT counterpart in vitro nor develop ampi-
cillin tolerance. Together, our results highlight the complex interplay between streptococcal
phages and their hosts, and provide insight into a potential role for streptococcal phages or
phage-derived products for the treatment of severe infections.
2. Materials and Methods
2.1. Bacterial Strains
The bacterial strains used in this study are listed in Table 1. S. pyogenes strains were
grown in either Todd Hewitt Broth (THB) or Brain Heart Infusion broth (BHI) without
shaking at 37 ◦C and 5% CO2. TSA blood agar (TrypticaseTM Soy Agar, Becton Dick-
inson, Heidelberg, Germany) supplemented with 3% defibrinated sheep blood (Xebios
Diagnostics, Düsseldorf, Germany) was used for cultivation on solid medium.
Table 1. S. pyogenes strains used in this study.
Strain Description Origin
ATCC 12202 Streptococcus pyogenes Rosenbach(ATCC® 12202™) ATCC database
SF370 Streptococcus pyogenes Rosenbach(ATCC® 700294™)
Ferretti et al. 2001 [31] and Abbot
et al. 2007 [32]
SF370∆hasA SF370 with complete deletion of thehasA coding sequence Abbot et al. 2007 [32]
5448 Wild-type clinical STSS/NecrotizingFasciitis isolate
M. Walker, University of
Queensland, Australia [33]
5448AP Animal passaged variant of 5448containing a 1-bp insertion in covS
M. Walker, University of
Queensland, Australia [34]
ISS3348 Clinical isolate; 30-bp deletion in covS G. Teti, University of Messina, Italy
3348∆hasA ISS3348 with complete deletion of thehasA coding sequence Resch et al. 2016 [35]
2.2. Phage Propagation
S. pyogenes ATCC 12202 was grown overnight and diluted 1:100 into 25 mL of fresh
pre-warmed THB and incubated at 37 ◦C until mid-logarithmic phase (OD600 nm = 0.25)
was reached. At this point, CaCl2 was added to the culture to reach a final concentration of
10 mM. Phage A1 (ATCC 12202-B1) was added to achieve a final multiplicity of infection
(MOI) of 0.1. After 20 min of incubation at 30 ◦C, the complete solution was transferred
into 100 mL fresh 10 mM CaCl2-containing THB and incubated for an additional 4 h at
37 ◦C. Solid NaCl was added to reach a final concentration of 1 M. The solution was stored
overnight at 4 ◦C and subsequently spun for 10 min at 10 000× g at 4 ◦C to pellet bacterial
debris. The supernatant was filtered using a 0.22 µm filter and subjected to ultracentrifuga-
tion for 2 h at 50 000× g at 4 ◦C (SW32 Ti rotor, Optima XPN-100 ultracentrifuge, Beckmann
Coulter, Krefeld, Germany). The resulting pellet was resuspended in SM-buffer (100 mM
NaCl, 8 mM MgSO4, 50 mM Tris-HCl (pH 7.5)) and stored at 4 ◦C. Phage concentrations
were determined by plaque assays on double-layer BHI plates.
2.3. Bacteriophage A1-Membrane Vesicle Interaction Assays
S. pyogenes MVs were purified from late-logarithmic phase cultures (OD600 nm = 0.4)
according to a previously described method [35]. Briefly, bacterial cultures were cen-
trifuged first (9300× g, 10 min, 10 ◦C), after which the supernatants were transferred to
new tubes and centrifuged again to remove residual bacterial debris (18 600× g, 15 min,
10 ◦C). Supernatants were filtered twice through 0.22 µm pore polyethylsulfone (PES) mem-
branes (Thermofisher scientific, Darmstadt, Germany) and spotted on TSA blood plates
to confirm their sterility. These batches were centrifuged at 175,000× g for 4 h at 10 ◦C
(Ti45 rotor, Optima XPN-100 ultracentrifuge, Beckmann Coulter). The resulting pellets
were resuspended in 30 mL total volume phosphate-buffered saline (PBS) (Thermofisher
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scientific, Darmstadt, Germany), pooled, and centrifuged again at 175,000× g for 3 h at
10 ◦C. The resulting pellet was resuspended in a final volume of 1 mL of PBS prior to
quantification using Nanoparticle Tracking Analysis (NTA) (NS300, Malvern Panalytical,
Kassel, Germany).
MVs were mixed with 10 µL of Phage A1 in MOI ratios of 10, 1, 0.1:1000, respectively,
and added to 80 µL 10 mM CaCl2-containing THB. After 15 min of incubation, samples
were analyzed by electron microscopy (EM) as described below or added to a mid-log
culture of S. pyogenes strains SF370 (OD600 nm = 0.25) achieving a final MOI of 1, of which
200 µL was transferred into 96-well plates. The OD600 nm was measured at 37 ◦C and 5%
CO2 every 10 min for 4 h in a Synergy H1 microplate reader (BioTek, Bad Friedrichshall,
Germany). A control consisted of MVs alone, where SM-buffer substituted phage samples
were compared to pure phage infection. All experiments were performed in both technical
and biological triplicates.
2.4. Electron Microscopy and Image Analysis
Overnight cultures of S. pyogenes ATCC 12202 or SF370 were diluted 1:100 in fresh
THB medium and incubated until mid-logarithmic phase (OD600 nm = 0.25) was reached.
CaCl2 was supplied to the culture to reach a final concentration of 10 mM. Phage A1 was
added to achieve an MOI of 10 and fixed with 2.5% glutaraldehyde (GA) 5, 15, 25, 45,
60 and 90 min post-infection. For scanning electron microscopy (SEM), bacteria were
added directly onto poly-L-lysine-treated glass coverslips. The samples were post-fixed
in 0.5% osmium-tetroxide, tannic acid and osmium-tetroxide again. The coverslips were
then dehydrated in a graded ethanol series, dried in carbon dioxide at critical point and
vacuum coated with 3 nm carbon-platinum. Imaging was performed using a LEO 1550
(Zeiss, Oberkochen, Germany) scanning electron microscope using an in-lens detector at
20 kV acceleration voltage. For transmission electron microscopy (TEM), aliquots of phage
or phage:MV samples were applied to fresh glow discharged carbon-film-coated copper
grids and allowed to adsorb for 10 min. After three washes with distilled water, the grids
were contrasted with 4% phospho-tungstic-acid/1% trehalose, touched on filter paper
and air-dried. The grids were examined in a LEO 906 (Zeiss AG, Oberkochen, Germany)
electron microscope operated at 100 kV and images were recorded with a Morada digital
camera (SIS-Olympus, Münster, Germany). Images were processed and analyzed with
Fiji, an open source scientific image processing application (http://fiji.sc (accessed on
2 April 2021)).
2.5. One-Step Growth Analysis
One-Step Growth Curves (OSGCs) were performed to determine the latency period
and burst size of Phage A1 according to a previously described method [36]. Briefly, a
mid-log (OD600 nm = 0.25) culture of S. pyogenes ATCC 12202 in 10 mM CaCl2-containing
THB was infected with Phage A1 at an MOI of 1 and was allowed to adsorb for 10 min at
37 ◦C. The infected culture was centrifuged (4000× g for 3 min at RT, Heraeus Multifuge
X3R, Thermo Scientific) to remove not adsorbed phages and the pellet was resuspended
in 10 mL of pre-warmed 10 mM CaCl2-containing THB. A total of 100 µL of this culture
was transferred into 9.9 mL of fresh 10 mM CaCl2-containing THB and gently mixed. A
10-fold serial dilution of this mixture was prepared twice and incubated at 37 ◦C and 5%
CO2. Then, 100 µL samples were collected every 5–10 min (depending on the growth
phase identified by initial trials) from each flask for PFU determination by plaque assays on
double-layer BHI plates. S. pyogenes ATCC 12202 grown for 24 h in BHI served as plating
host. Plates were incubated at 37 ◦C and 5% CO2 overnight. Burst size was calculated by
dividing the average PFU after phage burst by the average amount of infection centers in
the latent phase. The latent period was determined by the moment the first increase in
PFU/mL was observed. OSGCs were performed in biological triplicates.
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2.6. Spectrophotometric Phage A1 Lysis Profile
Overnight cultures of S. pyogenes were diluted 1:100 in fresh THB medium and incu-
bated until mid-logarithmic phase (OD600 nm = 0.25) was reached. CaCl2 was added to the
culture to reach a final concentration of 10 mM. In total, 180 µL per condition was aliquoted
in wells of a 96-well plate, and Phage A1 was added to achieve MOIs ranging from 1 to
0.001, after which the OD600 nm of each culture was measured at 37 ◦C and 5% CO2 every
10 min for 4 h in a Synergy H1 microplate reader (BioTek, Bad Friedrichshall, Germany).
Averages and standard deviations are given for one out of three biological replicates in
triplicate per strain.
2.7. Phage A1 Efficiency of Plating on M1 Serotype S. pyogenes
Efficiency of plaquing (EOP) assays were performed by spotting serial dilutions of
Phage A1 onto M1 serotype S. pyogenes. Tested S. pyogenes strains were diluted 1:100
in fresh THB medium and incubated until mid-logarithmic phase (OD600 nm = 0.25) was
reached. Hyaluronidase was added in a final concentration of 68 µg/mL when necessary.
CaCl2 was added to the culture to reach a final concentration of 10 mM. A total of 250 µL
per culture was mixed with 4 mL of 10 mM CaCl2-containing 0.7% BHI soft agar (48 ◦C)
and directly poured onto pre-warmed BHI plates. After 15 min of solidification, 10 µL of
a 10-fold dilution series of Phage A1 was spotted onto the soft agar and allowed to soak
into the agar for 15 min. Plates were incubated overnight at 37 ◦C and 5% CO2. Counted
plaques were converted to PFU/mL.
2.8. Lysogeny and CRISPR Acquisition Testing
S. pyogenes strains in mid-log phase were infected with Phage A1 at an MOI of 0.1
and were incubated at 37 ◦C and 5% CO2 for 24 h. The pellet of 1 mL lysed culture was
resuspended in 100 µL fresh THB and plated on BA plates. After overnight growth, single
colonies were selected, passaged twice in THB and tested for Phage A1 resistance. Phage
resistance was examined by adding Phage A1 reaching MOIs of 0.1, 1, 10 and 100 to a
mid-log culture of lysogenized S. pyogenes strains in the presence of Ca2+. Infected cultures
were incubated for 4 h at 37 ◦C and 5% CO2 and pictured. The genomic DNA of resis-
tant colonies was subjected to PCR to screen for phage integration with primers specific
to Phage A1 (5′ GGGGGATAAAAATGAATGAAACGCT (F) and 5′ TGCGGACACTGA-
CAAAATTTTTGG (R1)) and primers that should not amplify an amplicon when the
Phage DNA is integrated (5′ GGGGGATAAAAATGAATGAAACGCT (F) and 5′ CGAATT-
TAGGAAGTTAATTTAGG (R2)). Primers that amplify the leader proximal part of the
CRISPR array until the first spacer already present in the native CRISPR array were used
to investigate CRISPR acquisition (Fw: 5′ GCTTTTCAAGACTGAAGTCTAGC and Rv: 5′
GCGCAAGAAGAAATCAACCAG).
2.9. Genomic DNA Isolation
Phage A1 lysates were subjected to DNAse I (2 U/mL final concentration) and RNaseA
(100 µg/mL final concentration) treatment for 30 min at 37 ◦C. EDTA was added to a final
concentration of 5 mM, mixed and incubated for 10 min at 70 ◦C. Hereafter, genomic
DNA from 109 PFUs was extracted using a Phage DNA Isolation Kit according to the
manufacturer’s protocol (Norgen Biotek corp., Thorold, Canada). Genomic DNA from
S. pyogenes was isolated using the NucleoSpin® Microbial DNA kit (Macherey-Nagel,
Düren, Germany) and purified with a genomic DNA Clean & Concentrator kit (Zymo
research, Freiburg, Germany). Both Phage A1 and S. pyogenes DNA concentrations were
determined by NanoDrop and DNA integrity was verified in a 0.7% agarose gel.
2.10. Genome Sequencing and Bioinformatic Analysis
A total of 750 ng of Phage A1 genomic DNA was used to generate the DNA library
that was sequenced with 150 bp paired-ends using a NovaSeq 6000 system (Illumina
Inc., San Diego, CA, USA). Whole Genome Sequencing (WGS) reads were trimmed using
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Trimmomatic [37] version 0.38. Trimmomatic was supplied with the following parameters:
{ILLUMINACLIP:$ADAPTORS:2:30:10 LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15
MINLEN:25 HEADCROP:3}, where $ADAPTORS is a fasta file containing TruSeq adapters
and the sequence of the PhiX sequencing control. Trimmed read fastq files were down
sampled to 250,000 paired-end reads using the linux utility ‘head –n 100000’. Contigs were
assembled using Spades [38] version 3.12.0 in paired-end mode with default parameters.
The resulting viral genome was annotated using Prokka [39] version 1.13.7. Prokka was
supplied with the following parameters: {–kingdom Viruses–proteins KT388093.1.gb–prefix
phage}. Remaining hypothetical proteins were manually investigated for homology using
BlastP. Phage A1 genome accession number: MW495853.
2.11. Phylogenetic Analysis
Streptococcal phage genomes were downloaded from the NCBI database and phy-
logenetic studies based on whole phage genomes were performed using VICTOR [40].
All pairwise comparisons of the nucleotide sequences were conducted using the Genome-
BLAST Distance Phylogeny (GBDP) method under settings recommended for prokaryotic
viruses [40]. The branch lengths are scaled in terms of the GBDP distance formula D0 [40].
Branch support was inferred from 100 pseudo-bootstrap replicates each. Trees were rooted
and visualized with FigTree v1.4.4.
2.12. Cell Line Maintanance and Differentiation
The B-cell Leukaemia C/EBPα (CCAAT-enhancer-binding protein α, where CCAAT
stands for a Cytosine-Cytosine-Adenosine-Adenosine-Thymidine motif) Estrogen Recep-
tor clone 1 cell line (BLaER1) [41] was kindly provided by Prof. Thomas Graf (Centre
for Genomic Regulation, Barcelona). BLaER1 cells were maintained in RPMI medium
supplemented with 1% L-Glutamine, 1% penicillin-streptomycin (P/S, Sigma-Aldrich,
Darmstadt, Germany), 10% FBS and 1% sodium pyruvate (Thermofisher scientific, Darm-
stadt, Germany). BLaER1 cells were transdifferentiated into monocyte-like cells for 7 days
in six-well plates by seeding 1 × 106 cells/well in 3 mL of medium supplemented with
10 ng/mL of human recombinant IL-3, 10 ng/mL of human recombinant Macrophage
Colony-stimulating Factor 1 (both from PeproTech, Hamburg, Germany) and 100 nM of
β-Estradiol (Sigma-Aldrich, Darmstadt, Germany). Half of the medium was exchanged
at days 2 and 5 for fresh medium containing identical supplements. On day 7 after dif-
ferentiation, cells were harvested, counted with a CASY cell counter and cells were spun
down (500× g, 5 min, RT). Cell pellets were resuspended in an adjusted volume of fresh
medium without cytokines or P/S at a final density of 1 × 106 cells/mL. Finally, 106 cells
were seeded per well in a 24-well plate for infection assays.
2.13. Infection Assay
S. pyogenes strains in late-log phase (OD600 nm = 0.4) were spun down (6000× g, 3 min,
RT) and washed once with 1 mL of phosphate-buffered saline (PBS). Bacterial suspensions
were passed 10 times through a 27 Gauge syringe insert (NeoLab, Heidelberg, Germany)
in a 1 mL syringe (VWR) to separate the cocci chains, and 106 BLaER1 cells were infected
at MOI 1. Plates were centrifuged (300× g, 5 min, RT) to synchronize the infection. P/S
was added after 1 h to a final concentration of 1% to inhibit bacterial replication and
excessive cell death. After overnight incubation, plates were centrifuged (500× g, 5 min,
RT), after which supernatants were collected and stored at −20 ◦C until use. Supernatants
were thawed on ice and IL-6 and IL-1β concentrations were measured using Enzyme-
Linked ImmunoSorbent Assay (ELISA) kits (Thermofisher Scientific, Darmstadt, Germany)
according to the manufacturer’s protocol. ELISA data were analyzed by extrapolating
values of each sample from the standard curve using a log-log fit. The standard curve
was generated for each plate by plotting the logarithm of the absorbance of the standards
against the logarithm of the concentrations of each standard. In contrast, fresh supernatants
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were used to measure cell death using the Lactate Dehydrogenase (LDH)-Cytotoxicity
Assay Kit II (Abcam, Cambridge, UK) according to the manufacturer’s instructions.
2.14. Antibiotic Susceptibility
The susceptibility of S. pyogenes and their lysogenized variants to the commonly used
antibiotic ampicillin to treat S. pyogenes infections was tested. S. pyogenes strains were
grown on BA plates and harvested in sterile PBS. S. pyogenes suspensions were set at
~0.5 McFarland and swabbed onto Mueller-Hinton II agar (MH-II) plates (Sigma-Aldrich,
Darmstadt, Germany). Ampicillin E-tests (bestbion dx, Köln, Germany) were placed in
the middle of the plate and plates were incubated overnight at 37 ◦C with 5% CO2. The
minimum inhibitory concentration (MIC) was determined after 24 h.
2.15. Statistics
Paired t tests or one-way ANOVA tests were performed for comparisons between
data sets. All analyses were performed using Prism GraphPad software v8.0.0 (GraphPad
software Inc., San Diego, CA, USA). p < 0.05 was considered statistically significant.
3. Results
3.1. Virion Morphology and Physiological Characterization of S. pyogenes Bacteriophage A1
S. pyogenes Bacteriophage A1 (Phage A1) was obtained from the ATCC database and,
after obtaining high titer phage stocks, the morphology of Phage A1 was investigated
by both TEM and SEM. The obtained EM images revealed that Phage A1 virions have
icosahedral heads and long non-contractile tails (Figure 1A,B), typical for the Siphoviridae
family among the Caudovirales order. In total, 30 isolated phages in TEM images were
measured to determine phage dimensions, which are summarized in Table 2. We continued
with the investigation of the physiological properties of Phage A1. First, we examined
the lysis profile of Phage A1 on S. pyogenes strain ATCC 12202 (Figure 1C). Phage A1
exhibited a strong lytic phenotype at MOI 1 and this lytic phenotype was still present at
MOI 0.05 with rapid lysis of the culture occurring after 1.5 h of infection. However, we
observed a clear delay in lysis or no lysis occurring at MOI 0.01 or lower. Additionally,
cultures were not cleared after overnight incubation at lower MOIs starting from MOI 0.01.
We performed one-step growth curves (OSGCs) to determine the lag phase and average
number of newly produced phages per infected cell. Phage A1 showed a latent period of
40 min, after which the first increase in PFUs was observed. Additionally, the burst size of
Phage A1 is approximately 31 PFUs per infected cell on strain ATCC 12202 (Figure 1D).




Figure 1. Phage A1 morphology and growth characteristics. (A) TEM micrograph of purified Phage A1; (B) SEM micro-
graph of Phage A1 bound to S. pyogenes ATCC 12202 at multiplicity of infection (MOI) 25 after 10 min of coincubation; (C) 
Bacteriolytic activity of Phage A1 on S. pyogenes ATCC 12202 infected at different MOIs over time. Each curve shows mean 
values ± SD of one out of three experiments in triplicates; (D) One-step growth curves (OSGCs) of Phage A1 on S. pyogenes 
ATCC 12202. Mean values ± SD from three independent experiments are shown. 
Table 2. Phage A1 characteristics. 
Phage Parameter  Bacteriophage A1 (nm ± SD *) 
Head 60 ± 2 
Tail length 187 ± 4 
Tail width 10 ± 1 
Baseplate width 16 ± 2 
Total length 249 ± 3 
* Standard Deviation. 
3.2. Genome Sequence and Phylogeny of S. pyogenes Bacteriophage A1 
To obtain a more complete understanding of the molecular basis of the Phage A1 
biology and its interaction with S. pyogenes, we first sequenced the genome of Phage A1. 
We determined that the Phage A1 genome is a circular dsDNA genome of 37,239 base 
pairs with a GC content of 37.9% (Figure 2A). In total, 52 putative gene products (Gps) 
were predicted, of which 23 encode hypothetical proteins that could not be identified by 
BlastP. The genomic organization of Phage A1 includes modules dedicated to gene regu-
lation, DNA replication, DNA restriction, genome packaging, phage morphology and bac-
terial lysis, which is often observed for the Siphoviridae family members. The genome does 
not encode a hyaluronidase and no known virulence genes were identified. About half of 
the Phage A1 genome is dedicated to DNA packaging, phage structure and host cell lysis. 
The lysis module contains two predicted holin genes in addition to a peptidoglycan hy-
drolase lysin. The other half of the Phage A1 genome consists of regions dedicated to gene 
regulation and DNA replication; however, the majority of predicted Gps encode hypo-
thetical proteins. Manual inspection of these hypothetical proteins resulted in some inter-
esting observations. For instance, the Gp located downstream of the Gp for lysin (Gp51) 
showed 51% identity to a prophage gene involved in external DNA acquisition inhibition 
called paratox. Furthermore, a large proportion of hypothetical proteins are conserved 
proteins with domains of unknown function (DUF) commonly detected in phages, which 
were previously shown to be a potential source of anti-host defense mechanisms [42]. In-
triguingly, gp6 in the Phage A1 genome harbors almost 99% identity to a putative DNA-
binding antitoxin component found in S. pyogenes strain GA40634. Lastly, we identified a 
putative site-specific integrase (Gp52) and a lysogeny control module in the genome of 
Phage A1. The integrase gene is identical to the integrase of Phage Str01 but is unrelated 
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Table 2. Phage A1 characteristics.
Phage Parameter Bacteriophage A1 (nm ± SD *)
Head 60 ± 2
Tail length 187 ± 4
Tail width 10 ± 1
Baseplate width 16 ± 2
Total length 249 ± 3
* Standard Deviation.
3.2. Genome Sequence and Phylogeny of S. pyogenes Bacteriophage A1
To obtain a more complete understanding of the molecular basis of the Phage A1
biology and its interaction with S. pyogenes, we first sequenced the genome of Phage A1.
We determined that the Phage A1 genome is a circular dsDNA genome of 37,239 base pairs
with a GC content of 37.9% (Figure 2A). In total, 52 putative gene products (Gps) were
predicted, of which 23 encode hypothetical proteins that could not be identified by BlastP.
The genomic organization of Phage A1 includes modules dedicated to gene regulation,
DNA replication, DNA restriction, genome packaging, phage morphology and bacterial
lysis, which is often observed for the Siphoviridae family members. The genome does
not encode a hyaluronidase and no known virulence genes were identified. About half
of the Phage A1 genome is dedicated to DNA packaging, phage structure and host cell
lysis. The lysis module contains two predicted holin genes in addition to a peptidoglycan
hydrolase lysin. The other half of the Phage A1 genome consists of regions dedicated
to gene regulation and DNA replication; however, the majority of predicted Gps encode
hypothetical proteins. Manual inspection of these hypothetical proteins resulted in some
interesting observations. For instance, the Gp located downstream of the Gp for lysin (Gp51)
showed 51% identity to a prophage gene involved in external DNA acquisition inhibition
called paratox. Furthermore, a large proportion of hypothetical proteins are conserved
proteins with domains of unknown function (DUF) commonly detected in phages, which
were previously shown to be a potential source of anti-host defense mechanisms [42].
Intriguingly, gp6 in the Phage A1 genome harbors almost 99% identity to a putative DNA-
binding antitoxin component found in S. pyogenes strain GA40634. Lastly, we identified
a putative site-specific integrase (Gp52) and a lysogeny control module in the genome of
Phage A1. The integrase gene is identical to the integrase of Phage Str01 but is unrelated to
integrase genes found in S. pyogenes prophages. The most closely related integrase gene
was predicted in Streptococcus bovimastitidis with an identity of almost 83% (Table 3).
Since we identified a putative site-specific integrase along a lysogeny control module
in the genome of Phage A1, we hypothesized that Phage A1 could be a temperate phage
instead of a strictly lytic phage. To achieve a global overview of the relatedness of Phage
A1 to both Phage A25 and Phage Str01, but also to phages of other streptococcal species
and prophages present in S. pyogenes, we investigated the phylogenetic relatedness among
streptococcal phages. We included sequenced lytic and temperate phages of S. pyogenes,
S. pneumoniae, Streptococcus agalactiae, Streptococcus thermophilus, S. suis and Streptococcus
dysgalactiae in addition to annotated prophages found in various M-type S. pyogenes strains.
Initial alignments of the Phage A1 genome to lytic Phage A25 and temperate Phage Str01
already suggested that Phage A1 is highly similar to Phage A25 and Phage Str01. However,
the phylogenetic analysis based on whole phage genomes revealed that Phage A1, Phage
A25 and Phage Str01 form a separate branch in the generated phylogenetic tree (Figure 2B).
S. pneumoniae Phage MM1 is the most closely related phage to these three phages with
S. pyogenes prophages, S. suis and S. dysgalactiae phages being the most distantly related
(Figure S1). However, temperate Phage Str01 is the most similar phage to Phage A1,
further corroborating the possibility that Phage A1 is a temperate phage and not a strictly
lytic phage.
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Table 3. Phage A1 genome annotation.
Genomic Location (Gp Number) Identified Protein (Species) Direction Accession Number E Value Identity %
667..801 (Gp01) Hypothetical phage protein(S. pyogenes Phage 10270.2) <= ABF33863.1 1e−21 100
808..960 (Gp02) Hypothetical protein (S. pyogenes) <= WP_011054825.1 5e−27 100
971..1348 (Gp03) ImmA/IrrE family metallo-endopeptidase(S. pyogenes) <= WP_011054824.1 2e−86 100
1332..1691 (Gp04) XRE family transcriptional regulator(S. pyogenes Phage Str01) <= APZ81910.1 2e−79 100
1881..2099 (Gp05) Cro family anti-repressor (S. pyogenes Phage 10270.2) => ABF33867.1 2e−44 100
2194..2445 (Gp06) Putative DNA-binding antitoxin (S. pyogenes GA40634) => EPZ46884.1 4e−46 98.65
2476..2610 (Gp07) Hypothetical protein (S. pyogenes Phage 10270.2) => ABF33611.1 5e−24 100
2626..2940 (Gp08) Helix-turn-helix transcriptional regulator(S. pyogenes) => WP_011528544.1 2e−69 100
3167..3649 (Gp09) Hypothetical Gp157 family protein (S. pyogenes) => WP_011528545.1 2e−108 100
3650..4330 (Gp10) AAA family ATPase (S. pyogenes MGAS1882) => AFC68359.1 2e−164 99.56
4432..5661 (Gp11) DEAD/DEAH box helicase (Streptococcus sp.) => WP_011528546.1 0 100
5677..6135 (Gp12) DUF669 domain-containing protein (Streptococcus sp.) => WP_002995969.1 2e−107 100
6147..6950 (Gp13) Bifunctional DNA primase/polymerase (S. pyogenes) => WP_011528547.1 0 99.25
6940..8421 (Gp14) DNA primase (S. pyogenes) => WP_020905118.1 0 99.8
8666..8986 (Gp15) VRR-NUC domain-containing protein (S. pyogenes) => WP_002995960.1 7e−71 100
8970..9326 (Gp16) Hypothetical protein (S. pyogenes) => WP_011018138.1 4e−79 100
9323..9574 (Gp17) Hypothetical protein (S. pyogenes) => WP_011528549.1 4e−54 100
9568..9852 (Gp18) Hypothetical DUF3310-containing protein(S. pyogenes) => WP_011017568.1 5e−64 100
9849..10,118 (Gp19) Hypothetical protein (S. dysgalactiae) => SUN67275.1 1e−58 98.88
10,170..10,409 (Gp20) Hypothetical TIGR01671 family protein (S. pyogenes GA40634) => ESA49192.1 6e−33 98.28
10,660..10,971 (Gp21) Hypothetical DUF1372-containing protein(S. dysgalactiae) => WP_081281150.1 9e−62 92.31
10,971..11,294 (Gp22) Hypothetical protein (S. pyogenes Phage Str01) => APZ81913.1 2e−70 100
11,287..11,517 (Gp23) Hypothetical protein (S. pyogenes Phage A25) => YP_009191526.1 2e−47 100
11,565..11,924 (Gp24) Endodeoxyribonuclease RusA (S. dysgalactiae) => WP_065359284.1 7e−81 97.48
11,917..12,297 (Gp25) Hypothetical protein (S. pyogenes Phage Str01) => APZ81908.1 7e−86 100
12,364..13,035 (Gp26) Hypothetical DUF4417-containing protein(S. dysgalactiae) => WP_155778398.1 3e−164 98.21
13,005..13,415 (Gp27) Hypothetical protein (S. pyogenes Phage Str01) => APZ81907.1 2e−87 100
13,608..14,087 (Gp28) Terminase (small subunit) (S. dysgalactiae) => WP_003058573.1 6e−111 100
Viruses 2021, 13, 612 11 of 22
Table 3. Cont.
14,209..15,387 (Gp29) Terminase (large subunit) (S. dysgalactiae) => WP_003058577.1 0 100
15,399..16,976 (Gp30) Portal protein (S. dysgalactiae) => WP_003058556.1 0 100
16,979..18,127 (Gp31) Minor capsid protein (S. dysgalactiae) => WP_003058578.1 0 100
18,274..18,837 (Gp32) Scaffolding protein (S. pyogenes Phage A25) => YP_009191535.1 2e−129 100
18,856..19,734 (Gp33) Major capsid protein (Streptococcus canis) => WP_164406187.1 0 97.26
19,745..19,981 (Gp34) Hypothetical protein (S. dysgalactiae) => WP_003058596.1 3e−46 100
20,025..20,417 (Gp35) Hypothetical protein (S. dysgalactiae) => WP_003058548.1 9e−91 100
20,407..20,733 (Gp36) Minor capsid protein (S. pyogenes Phage Str01) => APZ81883.1 8e−70 100
20,733..21,092 (Gp37) Capsid protein (S. pyogenes Phage A25) => YP_009191540.1 4e−82 100
21,092..21,511 (Gp38) Capsid protein (S. dysgalactiae) => WP_155783005.1 4e−96 100
21,504..21,962 (Gp39) Major tail shaft protein (S. pyogenes Phage A25) => YP_009191542.1 6e−107 100
21,977..22,345 (Gp40) Hypothetical protein (S. dysgalactiae) => WP_155783003.1 1e−81 100
22,345..22,929 (Gp41) Hypothetical Gp15 protein (Streptococcus equi subsp. zooepidemicus) => KIS17966.1 4e−88 68.39%
22,946..26,617 (Gp42) Tail tape measure protein (S. pyogenes Phage Str01) => APZ81886.1 0 100
26,626..28,116 (Gp43) Tail endopeptidase (S. pyogenes Phage Str01) => APZ81874.1 0 100
28,120..30,381 (Gp44) Minor structural tail protein (S. pyogenes Phage A25) => ALF02720.1 0 100
30,393..32,258 (Gp45) Structural tail protein (S. pyogenes Phage A25) => ALF02721.1 0 100
32,291..32,737 (Gp46) Hypothetical DUF1366-containing protein(S. dysgalactiae) => WP_003058584.1 5e−97 99.3
32,703..32,930 (Gp47) Hypothetical protein (S. pyogenes Phage Str01) => APZ81920.1 4e−45 100
32,938..33,405 (Gp48) Class I Holin (S. pyogenes Phage A25) => YP_009191551.1 2e−106 98.71
33,398..33,733 (Gp49) Class III Holin (S. dysgalactiae) => WP_003058565.1 6e−74 100
33,708..35,180 (Gp50) Lysin (S. pyogenes Phage A25) => YP_009191553.1 0 100
35,318..35,509 (Gp51) Hypothetical Paratox protein (S. pyogenes) => WP_136110174.1 2e−06 51.22
35,552..36,991 (Gp52) Hypothetical Recombinase family protein(S. bovimastitidis) <= WP_071794279.1 0 82.88
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3.3. Phage A1 Is Potentially Temperate and Phage A1 Survivors Acquire Phage Resistance
To test whether Phage A1 could be a temperate phage, we assessed its ability to
integrate into the genome of S. pyogenes strains ATCC 12202 and SF370. Cultures in mid-
logarithmic growth phase were infected with Phage A1, after which we spun down cleared
lysates and plated pellets on blood agar plates to check for viable clones. To omit the
possibility of picking up contaminating phage DNA, single colonies were selected and
passaged twice before testing for the presence of Phage A1 products by PCR. The genomic
DNA of phage-surviving colonies was subjected to PCR to screen for phage integration
with primers specific to Phage A1 and primers that should not yield a product when the
Phage DNA is integrated into the host genome (Figure 3A top). We could amplify a product
from the genomic DNA of 6 of 14 SF370 and 13 of 15 ATCC 12202-surviving colonies when
we screened for the Phage A1 integrase gene (Figure 3A bottom). In contrast, no amplicons
could be detected when the PCR covered the circularization junction of the Phage A1
genome (Figure 3A), confirming that the Phage A1 genome is present in the isolated S.
pyogenes genomic DNA.
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Having established that Phage A1 DNA is present in S. pyogenes after infection, we
investigated whether phage-surviving S. pyogenes clones become resistant to Phage A1
infection. We infected three Phage A1-surviving clones and their WT S. pyogenes strains
with Phage A1 at MOIs ranging from 0.1 to 100. Phage A1-surviving clones of both ATCC
12202 and SF370 were able to grow even when infected at an MOI of 100. In contrast, WT
strains were rapidly cleared when infected at MOI 0.1 for ATCC 12202 or MOI 1 for SF370
(Figure 3B).
3.4. Phage A1-Surviving Strains Do Not Alter the Host Immune Response or Tolerance
to Antibiotics
Phage lysogeny has the potential to alter phenotypes of their hosts. Therefore, we
investigated whether Phage A1 survivors behave differently than their WT counterparts.
First, we determined growth characteristics to investigate the fitness of survivor strains. We
observed a prolonged lag phase for all three tested ATCC 12202 phage-surviving clones, and
these strains did not reach equal ODs when entering stationary growth phase. In contrast,
each isolated phage-surviving SF370 strain behaved differently when compared to each
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other or to WT SF370. Surviving clone 1 grew equally during lag phase and early log phase
but entered stationary phase earlier. Surviving clone 2 grew equal to WT but reached a
higher OD. Surviving clone 3 showed a prolonged lag phase, similar to phage survivor
ATCC 12202 strains (Figure S2).
Since the antibiotic treatment failure of severe S. pyogenes-associated disease has
been reported and phage therapy could provide an alternative, we examined whether the
pathogenicity of Phage A1 survivors was affected in comparison to WT S. pyogenes. In the
body, after S. pyogenes invades soft tissue and establishes systemic infection, it encounters
various types of immune cells. Here, monocytes fulfil crucial functions during bacterial
infection such as phagocytosis, antigen presentation and cytokine production [43]. We used
BLaER1 cells to represent the encountered monocytes during systemic infection. BLaER1
are immortalized, genetically modified B-cells from a leukemia patient that stably express
an inducible C/EBPα transgene. Induction of the transcription factor C/EBPα leads to
the irreversible differentiation of BLaER1 cells into monocyte-like cells which recapitulate
monocytic functions [41]. First, we investigated cytokine production by BLaER1 cells
after infection with WT S. pyogenes SF370 and phage-surviving strains. We observed that
infection with both WT and Phage A1 survivors results in a clear proinflammatory response,
but found no difference in the amount of IL-6 or IL-1β produced by cells infected with
WT SF370 compared to Phage A1 lysogen-infected cells (Figure 4A). Continuing to test the
pathogenicity of Phage A1 survivors, we measured LDH release to determine the cytotoxic
ability upon infection. In agreement with the cytokine profiles, we did not detect significant
differences in released LDH in culture medium after infecting BLaER1 cells with WT SF370
or Phage A1-surviving strains (Figure 4B).
As the tolerability of S. pyogenes towards antibiotics can be influenced upon phage
lysogenization or chromosomal insertion of prophage-associated genetic elements [44],
we investigated the antimicrobial resistance profile against the commonly used antibiotic
ampicillin. Here, we observed that Phage A1-surviving strains are not enhanced in their
ability to grow in the presence of ampicillin, showing no increase in MIC (Figure 4C).
3.5. CRISPR-Cas-Mediated Spacer Acquisition Is Increased in the Absence of a Capsule
It is well known that S. pyogenes produces an HA capsule, which has been shown to
play an important factor in the defense against phage infection or in immune evasion [16–18].
However, capsule production differs greatly among strains and under different growth
conditions [45]. To examine the importance of the capsule in the defense against Phage A1
infection, we investigated the lysis profile of Phage A1 on commonly studied S. pyogenes
SF370 and clinical isolate S. pyogenes ISS3348. The latter strain contains a naturally occurring
mutation in covRS resulting in enhanced capsule production. Additionally, hasA KO
mutants of SF370 and ISS3348 were tested to identify the role of the capsule during Phage
A1 infection. S. pyogenes SF370 showed rapid lysis after Phage A1 infection at MOI 1
and MOI 0.5, but was delayed at MOI 0.1. A minor decrease in OD was observed after
overnight infection at MOI 0.05 and no lysis was observed at lower MOIs than 0.05. The
lytic phenotype on SF370∆hasA was increased compared to WT SF370, with accelerated
lysis occurring up to MOI 0.05. Lysis at MOI 0.01 could not be detected. In contrast, ISS3348
showed a completely resistant phenotype to Phage A1 infection with no lysis occurring
at the tested MOIs. However, the lysis profile of Phage A1 on ISS3348∆hasA was similar
to that of SF370, showing that ISS3348 becomes susceptible to Phage A1 infection in the
absence of its capsule (Figure 5A).
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compared to wild type. (A) Overnight cytokine production by BLaER1 cells after infection with WT S.
pyogenes SF370 and phage-surviving strains. (B) The percentage of BLaER1 cell death after infection
with Phage A1 survivors or WT S. pyogenes SF370 is shown. (A,B) Mock: buffer control, S1: phage
survivor 1, S2: phage survivor 2 and S3: phage survivor 3; (C) Ampicillin susceptibility profiles of
S. pyogenes SF370 and survivor strains are shown. S1: phage survivor 1, S2: phage survivor 2 and
S3: phage survivor 3; (A–C) Pooled data from three or four independent experiments are shown.
Statistical significance between groups was determined by one-way ANOVA tests.
Since CovRS regulates the expression of up to 15% of the S. pyogenes genome—including
the hasABC operon—[46] it is not known whether an altered infection of ISS3348 would
be a direct consequence of the mutated covRS resulting in the thickened capsule or other
background-related factors compared to SF370. Therefore, we included S. pyogenes 5448 and
5448AP, which are identical except for an inactivated CovRS system in 5448AP [34]. We
assessed plaquing efficiency to confirm the ability of Phage A1 to infect the aforementioned
M1 serotype S. pyogenes strains and their mutants. Here, we confirmed that Phage A1
infectivity was slightly increased on SF370∆hasA compared to SF370. Additionally, Phage
A1 was unable to form PFUs on strain ISS3348 but we could detect PFUs on ISS3348∆hasA,
which were up to one order of magnitude less compared to WT SF370. The infection of
strain 5448 was 2.5 to 3 orders of magnitude lower compared to SF370, but PFU counts
showed a similar infection efficiency as on 5448AP (Figure 5B). To further verify that the
increased susceptibility of the hasA KO mutants is due to the absence of the capsule, we
included hyaluronidase in the growth medium of WT S. pyogenes strains to prevent capsule
formation and repeated EOP assays. Here, we confirmed that the infection efficiency
of Phage A1 was increased by around one order of magnitude when S. pyogenes was
grown in hyaluronidase-containing media, similar to the difference between WT SF370 and
SF370∆hasA without hyaluronidase in growth media (Figure S3 ). Strikingly, WT ISS3348
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shifted from a completely resistant phenotype to a susceptible phenotype when grown in
hyaluronidase-containing media. The infection of WT ISS3348 by Phage A1 was similar to
the infection of ISS3348∆hasA. The addition of hyaluronidase in the growth media had no
additional effect on the infection of ISS3348∆hasA, confirming that the S. pyogenes capsule
is pivotal in the defense against phage infection (Figure 5C).




Figure 5. Impaired capsule-based phage resistance results in more detectable CRISPR-Cas-mediated spacer acquisition. 
(A) Lysis profiles of Phage A1 on S. pyogenes SF370, ISS3348, and their isogenic ∆hasA strains. Each curve shows mean 
values ± SD of one out of three experiments in triplicates; (B) Phage A1 efficiency of plaquing (EOP) on various M1 sero-
type S. pyogenes, and their isogenic ∆hasA or CovS mutant strain; (C) Phage A1 EOP on S. pyogenes ISS3348 and 
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Lysis profiles of Phage A1 on S. pyogenes SF370, ISS3348, and their isogenic ∆hasA strains. Each curve shows mean values
± SD of one out of three exp riments in triplicates; (B) Phage A1 efficiency of plaquing (EOP) on various M1 serotype S.
p ogenes, and th ir isogenic ∆hasA or CovS mutant strain; (C) Phage A1 EOP on S. pyogenes ISS3348 and ISS3348∆hasA grown
in the absence or prese ce of hyaluronidas (H+); (B,C) Results are presented as mean v lues ± SD from three independent
experiments. p < 0.05 determined by paired t tests was considered statistically significant. * p < 0.05, ** p < 0.01, NS = not
significant; (D) Representative agarose gels showing amplified CRISPR arrays of WT S. pyogenes SF370 (up), SF370∆hasA
(down), and 9 surviving colonies (1–9) for both strains after Phage A1 infection.
Although Phage A1 infectivity was increased for the hasA KO mutants, we observed
that phage-surviving colonies in the absence of capsule c uld still be recovered after
overnight growth. Consequently, we investigat d intracellular mechanisms b whic S.
pyogenes could re ist phage infectio . We established a spa er acquisition assay dapted
from a previ us study [47] to test whether the typ II-A CRISPR-C s system of S. pyogenes
could acquire new spacers deriving from Phage A1. S. pyoge es SF370 and SF370∆hasA
were infected at MOI 1 after which the cl ared culture was probed for viable colonies
on blood plates. Surviving colonies were screened for spacer acquisition by PCR after
excluding the presence of Phage A1 DNA in the same strain. We detected the acquisition
of a new spacer in 2 out of 27 tested surviving single colonies of WT SF370. Interestingly,
we observed spacer acquisition in 12 out of the 27 tested single colonies in the hasA KO
strain. Additionally, multiple acquired spacers could be amplified from the genome of
SF370∆hasA, suggesting that spacer acquisition is increased in the absence of a capsule
(Figure 5D). Sequencing of acquisition events confirmed that the spacers derive from the
Phage A1 genome. The acquired spacers in WT SF370 targeted structural proteins encoding
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the major capsid protein (Gp33) and the minor structural tail protein (Gp44) in the genome
of Phage A1. In addition to Gps 33 and 44, the putative transcriptional regulator (Gp08),
DNA primase (Gp14), structural tail protein (Gp45) and the lysin (Gp50) were targeted in
SF370∆hasA (Figure S3B).
3.6. Membrane Vesicles of S. pyogenes Bind Phages and Limit Phage Infection
Assessing the lysogeny and CRISPR spacer acquisition of S. pyogenes SF370 showed
that the type II CRISPR-Cas system integrated new spacers into its CRISPR array and
that the strain was less efficiently lysogenized by Phage A1. In contrast, nearly all phage-
surviving S. pyogenes ATCC 12202 colonies contained detectable Phage A1 DNA. Further-
more, the capsule of ISS3348 seems to be the critical determinant in the defense against
phage infection. Therefore, we hypothesized that mechanisms by which S. pyogenes sur-
vives phage infection can vary among strains and are not restricted to lysogeny, the capsule
or CRISPR-Cas immunity. Another strategy by which bacteria can limit phage infec-
tion is by the increased production of MVs, which could potentially serve as a decoy
for phages [48]. To explore the potential role of S. pyogenes-derived MVs in the defense
against Phage A1 infection, we followed phage infection over time with SEM imaging after
infecting S. pyogenes SF370 with Phage A1 at an MOI of 10. Here, we observed that phages
are bound to their host after 5 min of incubation, and disturbed bacterial membranes and
potential MV formation became visible after 25 min of infection. MV production was
clearly observed after 45 min of infection. The first lysed cells appeared between 45 and
60 min of infection. Additionally, most S. pyogenes cells were lysed after 90 min (Figure 6A).
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Viruses 2021, 13, 612 17 of 22
To evaluate whether increased amounts of MVs produced by S. pyogenes are able to
limit phage predation, we incubated purified MVs of S. pyogenes SF370 with Phage A1
before infecting S. pyogenes SF370. Indeed, we observed the inhibition of phage infection
with phage:S. pyogenes:MV ratios of 1:1:1000 (Figure 6B). In contrast, we did not observe
the inhibition of phage infection when we infected S. pyogenes at higher phage to MV
ratios in favor of phage amounts (not shown), suggesting a concentration-dependent
inhibitory effect. To examine whether the observed neutralizing effect is due to the direct
binding of the phage to MVs, we visualized coincubated Phage A1 and purified S. pyogenes
SF370-derived MVs with TEM. Here, we observed that phages were bound to MVs after
15 min with clear individual contact between the phage tail and the MVs (Figure 6C). To
investigate whether the binding of Phage A1 to MVs is a general phenomenon among S.
pyogenes strains, we purified MVs from clinical isolate ISS3348 and tested the interaction
between Phage A1 and ISS3348-derived MVs. We observed that phages were bound to
MVs of ISS3348 after coincubation, and interaction between phage and MVs was observed
(Figure 6D).
4. Discussion
In this study, we describe a previously uncharacterized S. pyogenes phage in detail.
We show that Phage A1 is a putative temperate phage and that its DNA can be detected
in S. pyogenes genomes, resulting in strains that are resistant to subsequent infections.
Importantly, these Phage A1-survivor strains do not develop ampicillin tolerance or become
more virulent than their WT counterpart.
To date, the best-studied phage of S. pyogenes—that is not a prophage—is Phage A25.
Electron micrographs showed that Phage A25 belongs to the Siphoviridae [26], and although
minor differences exist in some phage dimensions, the morphology of Phage A1 is highly
similar to that of Phage A25. The estimated burst size of Phage A25 was determined at
12 to 32 PFU per bacterial cell depending on the host strain that was investigated [27,28].
Similarly, we observed an average burst of 31 PFUs per infected cell for Phage A1 when
propagated on S. pyogenes ATCC 12202. However, this number could differ when tested
on different S. pyogenes strains since the lysis profile also showed minor differences in the
infection cycle between S. pyogenes strains ATCC 12202 and SF370.
Streptococcal phages typically feature a modular genome organization with a clear
distinction between regions dedicated to phage structure and host cell modulation [49].
Recently, two S. pyogenes phage genomes were sequenced where this modular genetic
arrangement was observed as well [30,50]. The Phage A1 genome was highly similar to
temperate Phage Str01 and virulent Phage A25, with Phage Str01 being its closest relative.
Compared to Phage Str01, Phage A1 accommodates 37 more nucleotides in a non-coding
region dedicated to gene regulation and 132 nucleotides more in a hypothetical protein
produced by g23 that were present in the Phage A25 genome. Furthermore, we identified
two single nucleotide differences, one of which was a synonymous substitution in the
DNA primase. The other difference, however, was a non-synonymous mutation in the
DUF1366-protein changing a valine to isoleucine in comparison to Str01. Besides the
missing integrase gene and surrounding genetic regions in Phage A25, multiple (non-)
synonymous mutations were present in several structural proteins but also in hypothetical
proteins. Two amino acid changes were detected in the C-terminus of the class I Holin,
which were not present in the Phage Str01 genome. One of the Phage A1 genes (g52)
shared identity with a recombinase family protein found in S. bovimastitidis and is identical
to the site-specific integrase gene of Phage Str01, which is noteworthy since Phage A1 is
historically implicated to be a strictly lytic phage [18,24]. Here, we observe that the integrase
gene locates in the vicinity of the gene regulation module, which is expressed early during
infection (data not shown). Early expressed genes may be involved in lysogenic–lytic
lifecycle decisions, and local transcript levels could therefore determine which replication
cycle the phage enters, e.g., high concentrations of integrase transcripts promoted a lysogenic
state of mycobacteriophages upon infection [51]. Phage A25 escaped from lysogeny by the
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deletion of its integrase [30], and, based on the genomic similarity and differences between
Phage Str01, Phage A25 and Phage A1, it is tempting to speculate that Phage A1 served
as an intermediate phage in the conversion of Phage A25 from a temperate to a strictly
lytic phage.
PCR analysis showed that Phage A1 DNA can be amplified from the genome of
nearly all S. pyogenes ATCC 12202- and some SF370-surviving colonies, indicating that
Phage A1 could be a temperate phage. Furthermore, surviving Phage A1 infection in
both parental S. pyogenes strains resulted in complete resistance against subsequent phage
infections, most likely by providing superinfection immunity. Previous hints towards
superinfection immunity against Phage A25 were found by McCullor and colleagues,
where they observed that S. pyogenes strains containing high homology prophages to Phage
A25 were resistant to infection [30]. The mechanism of resistance was experimentally
confirmed by complementing the cI-like repressor and regulation module of an S. pyogenes
prophage—representing the deleted lysogeny module that is absent in Phage A25 but
present in Phage A1—in multiple strains that were susceptible to Phage A25 infection. As a
result, complemented strains converted into phage-resistant strains through the expression
of the cI-like repressor, which prevents the transcription of invading homologous phages
and terminates phage replication [30].
S. pyogenes is one of the most clinically relevant human pathogens causing over
500,000 deaths each year [6]. Prophages in the genome of S. pyogenes have been shown
to be a major contributor to virulence of this pathogen by transmitting virulence factors
that altered its pathogenic behavior [52–54]. We did not identify known virulence genes in
the genome of Phage A1, but previous studies have shown that lysogeny can significantly
influence the host cell by altering the bacterial surface or transduce virulence factors
to other host cells [55]. Our lab and others previously described the temperate phage-
mediated transfer of the streptococcal superantigen genes ssa [56] and speA [57] among
clinical S. pyogenes isolates. Nevertheless, phage therapy holds great potential to treat
complicated infections where antibiotics are ineffective. Because temperate phages have the
ability to integrate into host genomes and mediate the transfer of potential virulence genes
between bacteria, strictly lytic phages are preferred subjects for therapeutic purposes [58].
In this study, however, we did not observe an increased antibacterial resistance phenotype
or pathogenicity of Phage A1 survivors compared to WT bacteria, which holds promise
for the development of Phage A1 or Phage A1-derived products for therapeutic uses. For
instance, Phage A1 could be engineered towards a lytic phage by the removal of the putative
integrase, or to disturb intracellular processes that are important for bacterial survival after
lysogenization [59]. However, Phage A1 survivors displayed a superinfection immunity
phenotype and were insensitive to subsequent phage infections. Additionally, early studies
have described increased virulence of phage-surviving S. pyogenes, showing that phage
survivors were enhanced in their ability to kill mice [24], although a real estimation of
virulence is difficult due to discrepancies between our infection model and mouse models
used in the 1950s. In conclusion, a cautious approach towards temperate phages in phage
therapy should be kept in mind and we suggest the development of phage endolysins from
streptococcal phages for their antibacterial potential over the therapeutic use of Phage A1
itself, to support the treatment of severe streptococcal disease where antibiotics failed to
resolve the infection [60].
The hyaluronic acid capsule is a major virulence determinant for S. pyogenes and highly
encapsulated S. pyogenes strains are associated with more severe disease and increased
resistance to neutrophil-mediated killing [16,17]. Moreover, the removal of the HA capsule
increased the phage sensitivity of S. pyogenes [18,30]. Here, we were able to confirm the
critical role of the capsule in phage defense. We observed that Phage A1 infects SF370 as
efficiently as its replication strain ATCC 12202 but did not propagate in S. pyogenes ISS3348.
S. pyogenes ISS3348 is a clinical isolate with a mutation in the two-component regulatory
system CovRS. Mutations in CovRS have been shown to result in highly encapsulated
S. pyogenes strains and could explain the observation that ISS3348 is resistant to phage
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infection since increased capsule production blocks phage adsorption [14]. In agreement,
Phage A1 infection of ISS3348 was observed when hasA was deleted from the genome or
when the capsule was removed by enzyme treatment in the growth media, confirming
that the capsule is a direct cause of impenetrability. However, we observed equal infection
efficiencies of Phage A1 on S. pyogenes strains 5448 and 5448AP, indicating that background-
related factors in addition to the thickness of the capsule are involved in phage resistance
and can differ between strains.
Interestingly, we observed that the type II-A CRISPR-Cas system of SF370∆hasA
showed elevated spacer acquisition events compared to WT spacer acquisition levels.
Previous studies showed that CRISPR loci were among the most highly transcribed regions
in bacterial cells during normal growth [61,62], suggesting that the high-level expression of
CRISPR-Cas systems does not result in fitness defects and is advantageous for survival,
at least in some environments. In agreement, no differential expression of the type II-C
CRISPR-Cas genes in C. jejuni was observed upon phage infection [63]. Therefore, we
hypothesized that native expression levels of the SF370 CRISPR-Cas system are sufficient
for phage defense but the increased entry of Phage A1 into cells without a capsule and
the involved dynamics hereof resulted in increased phage recognition by the CRISPR-Cas
system. Until now, the CRISPR-Cas system of S. pyogenes has not been investigated in
its native host due to the previous lack of infectious elements to challenge S. pyogenes.
Although the type II-A CRISPR-Cas system has been studied extensively in a heterologous
host [47,64], it would be most important to study the type II-A CRISPR-Cas system in its
native settings. For instance, host-specific factors are absent in previous experimental set-
ups and could play important parts in CRISPR immunity, as shown for other organisms [65].
Based on our results, Phage A1 and S. pyogenes SF370∆hasA provide an ideal system to
study the CRISPR-Cas system to gain a deeper understanding of CRISPR-Cas biology in
its original host, which ultimately could lead to the optimization of CRISPR-Cas9-based
tools for biotechnological purposes.
Another characteristic of S. pyogenes strains that acquired covRS mutations is the
hyper production of MVs [35]. MVs are naturally secreted by cells of all kingdoms of life
and exhibit a large diversity of biological roles [66]. Because the surface of MVs is highly
similar to that of their host cells, MVs can serve as a decoy for phages and limit phage
infection [66,67]. In this study, we observed highly disturbed bacterial membranes and
MV formation during the course of infection. Additionally, incubating purified MVs of
S. pyogenes SF370 with Phage A1 before the infection of S. pyogenes SF370 inhibited phage
infection. We could further show that the observed neutralizing effect is due to direct
binding of the phage to MVs that could also be applied to other strains of S. pyogenes.
Other studies have reported similar observations. Escherichia coli outer membrane vesicles
(OMVs) were shown to neutralize bacteriophage T4 by the formation of complexes between
phage and OMVs [48]. Moreover, the OMVs of Vibrio cholerae reduced phage infection in
a dose- and receptor-dependent manner [67], providing evidence that MVs act as a first
line of defense against phage predation that can be applied to a large variety of bacterial
species. However, the extent to which MVs contribute towards the phage resistance of
S. pyogenes in natural habitats is less understood since the concentrations of MVs that
naturally accumulate during infection are unknown. Additionally, mutants of S. pyogenes
that are unable to produce MVs have not been obtained to date, which makes it impossible
to quantify the role that MVs play during infection. Nevertheless, it is reasonable to assume
that MVs can be protective of phage infection when a desirable ratio of MVs and phages
has accumulated in its micro-environment.
In summary, we propose a multistage interaction model between S. pyogenes and
Phage A1.
MVs produced by S. pyogenes are able to scavenge phage particles from the environ-
ment and reduce the infection pressure. When phages reach the cell surface of S. pyogenes,
they have to overcome a hyaluronic acid capsule to bind to their receptor. When a phage
manages to bind its receptor and injects its DNA into S. pyogenes, new phages are produced
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in the majority of infected cells, which are released during cell burst. When the capsule is
absent or reduced in thickness, phage infectivity is increased and intracellular anti-phage
defense systems—such as CRISPR-Cas—become more prominent. In a minor fraction of
infected cells, the Phage A1 genome becomes present in the S. pyogenes genome enabling
the survival of the bacterial host. However, Phage A1-surviving clones do not become more
virulent than their WT counterpart in vitro or develop resistance towards ampicillin. In
conclusion, this work provides novel insight into survival strategies utilized by S. pyogenes
to combat phage predation and describes a means to study the type II-A CRISPR-Cas
system in its native host. Lastly, we propose that Phage A1 gene products—such as the
endolysin—have the potential to be harnessed for the development of anti-bacterial agents.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/v13040612/s1, Figure S1: Extended phylogeny of Phage A1 to streptococcal phages based on
whole genomes; Figure S2: Growth curves of WT ATCC 12202 (left), WT SF370 (right) compared to
three potential Phage A1 lysogens each; Figure S3: (A) Phage A1 plaquing on SF370 in the absence
and presence of hyaluronidase in growth medium. Mean values ± SD from three independent
experiments are shown. (B) Alignment of acquired spacer sequences in WT SF370 (top) or SF370∆hasA
(bottom) phage survivors to the Phage A1 genome highlighted in red on the dark yellow bar, marked
by asterisks.
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Nowicki, G.; et al. Two novel temperate bacteriophages infecting Streptococcus pyogenes: Their genomes, morphology and stability.
PLoS ONE 2018, 13, e0205995. [CrossRef]
51. Broussard, G.W.; Oldfield, L.M.; Villanueva, V.M.; Lunt, B.L.; Shine, E.E.; Hatfull, G.F. Integration-Dependent Bacteriophage
Immunity Provides Insights into the Evolution of Genetic Switches. Mol. Cell 2013, 49, 237–248. [CrossRef] [PubMed]
52. Kaplan, E.L.; Wotton, J.T.; Johnson, D.R. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis.
Lancet 2001, 358, 1334–1337. [CrossRef]
53. Ikebe, T.; Wada, A.; Inagaki, Y.; Sugama, K.; Suzuki, R.; Tanaka, D.; Tamaru, A.; Fujinaga, Y.; Abe, Y.; Shimizu, Y.; et al.
Dissemination of the Phage-Associated Novel Superantigen Gene speL in Recent Invasive and Noninvasive Streptococcus pyogenes
M3/T3 Isolates in Japan. Infect. Immun. 2002, 70, 3227–3233. [CrossRef]
54. Banks, D.J.; Lei, B.; Musser, J.M. Prophage Induction and Expression of Prophage-EncodedVirulence Factors in Group A
Streptococcus Serotype M3 StrainMGAS315. Infect. Immun. 2003, 71, 7079–7086. [CrossRef]
55. Bondy-Denomy, J.; Qian, J.; Westra, E.R.; Buckling, A.; Guttman, D.S.; Davidson, A.R.; Maxwell, K.L. Prophages mediate defense
against phage infection through diverse mechanisms. ISME J. 2016, 10, 2854–2866. [CrossRef]
56. Vojtek, I.; Pirzada, Z.A.; Henriques-Normark, B.; Mastny, M.; Janapatla, R.P.; Charpentier, E. Lysogenic Transfer of Group
AStreptococcusSuperantigen Gene among Streptococci. J. Infect. Dis. 2008, 197, 225–234. [CrossRef]
57. Weeks, C.R.; Ferretti, J.J. The gene for type a streptococcal exotoxin (erythrogenic toxin) is located in bacteriophage T12. Infect.
Immun. 1984, 46, 531–536. [CrossRef]
58. Monteiro, R.; Pires, D.P.; Costa, A.R.; Azeredo, J. Phage Therapy: Going Temperate? Trends Microbiol. 2019, 27, 368–378. [CrossRef]
[PubMed]
59. Park, J.Y.; Moon, B.Y.; Park, J.W.; Thornton, J.A.; Park, Y.H.; Seo, K.S. Genetic engineering of a temperate phage-based delivery
system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus. Sci. Rep. 2017, 7, srep44929. [CrossRef] [PubMed]
60. Fischetti, V.A. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. Viruses 2018, 10, 310. [CrossRef]
61. Dugar, G.; Herbig, A.; Förstner, K.U.; Heidrich, N.; Reinhardt, R.; Nieselt, K.; Sharma, C.M. High-Resolution Transcriptome Maps
Reveal Strain-Specific Regulatory Features of Multiple Campylobacter jejuni Isolates. PLoS Genet. 2013, 9, e1003495. [CrossRef]
[PubMed]
62. Dugar, G.; Leenay, R.T.; Eisenbart, S.K.; Bischler, T.; Aul, B.U.; Beisel, C.L.; Sharma, C.M. CRISPR RNA-Dependent Binding and
Cleavage of Endogenous RNAs by the Campylobacter jejuni Cas9. Mol. Cell 2018, 69, 893–905.e7. [CrossRef]
63. Sacher, J.C.; Flint, A.; Butcher, J.; Blasdel, B.; Reynolds, H.M.; Lavigne, R.; Stintzi, A.; Szymanski, C.M. Transcriptomic Analysis of
the Campylobacter jejuni Response to T4-Like Phage NCTC 12673 Infection. Viruses 2018, 10, 332. [CrossRef]
64. Heler, R.; Wright, A.V.; Vucelja, M.; Doudna, J.A.; Marraffini, L.A. Spacer Acquisition Rates Determine the Immunological
Diversity of the Type II CRISPR-Cas Immune Response. Cell Host Microbe 2019, 25, 242–249.e3. [CrossRef] [PubMed]
65. Nuñez, J.K.; Bai, L.; Harrington, L.B.; Hinder, T.L.; Doudna, J.A. CRISPR Immunological Memory Requires a Host Factor for
Specificity. Mol. Cell 2016, 62, 824–833. [CrossRef]
66. Tsatsaronis, J.A.; Franch-Arroyo, S.; Resch, U.; Charpentier, E. Extracellular Vesicle RNA: A Universal Mediator of Microbial
Communication? Trends Microbiol. 2018, 26, 401–410. [CrossRef] [PubMed]
67. Reyes-Robles, T.; Dillard, R.S.; Cairns, L.S.; Silva-Valenzuela, C.A.; Housman, M.; Ali, A.; Wright, E.R.; Camilli, A. Vibrio cholerae
Outer Membrane Vesicles Inhibit Bacteriophage Infection. J. Bacteriol. 2018, 200. [CrossRef] [PubMed]
